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Abstract
Background: Vasospasm of the spiral modiolar artery (SMA) may cause ischemic stroke of the
inner ear. Endothelin-1 (ET-1) induces a strong, long-lasting constriction of the SMA by increasing
contractile apparatus Ca2+ sensitivity via Rho-kinase. We therefore tested several Rho-kinase
inhibitors and a cell-permeable analogue of cAMP (dbcAMP) for their ability to reverse ET-1-
induced constriction and Ca2+-sensitization.
Methods: The present study employed SMA isolated from gerbil temporal bones. Ca2+sensitivity
was evaluated by correlating vascular diameter and smooth muscle cell [Ca2+]i, measured by fluo-
4-microfluorometry and videomicroscopy.
Results: The Rho-kinase inhibitors Y-27632, fasudil, and hydroxy-fasudil reversed ET-1-induced
vasoconstriction with an IC50 of 3, 15, and 111 µmol/L, respectively. DbcAMP stimulated a dose-
dependent vasodilation (Ec50 = 1 mmol/L) and a reduction of [Ca2+]i (EC50 = 0.3 µmol/L) of ET-1-
preconstricted vessels (1 nmol/L). Fasudil and dbcAMP both reversed the ET-1-induced increase in
Ca2+ sensitivity.
Conclusion: Rho-kinase inhibition and dbcAMP reversed ET-1-induced vasoconstriction and
Ca2+-sensitization. Therefore, Rho-kinase inhibitors or cAMP modulators could possess promise
as pharmacological tools for the treatment of ET-1-induced constriction, ischemic stroke and
sudden hearing loss.
Background
The inner ear's blood supply depends solely on the spiral
modiolar artery (SMA), a functional end artery. Vasos-
pasm/constriction of the SMA can cause an ischemic
stroke of the inner ear, leading to sudden sensorineural
hearing loss (SSHL). Thus, investigating the mechanisms
controlling the inner ear microcirculation is a prerequisite
for the development of new strategies to treat SSHL.
Capillary blood flow is primarily regulated by the resist-
ance of precapillary arteries. The vascular resistance is a
function of the contractile status of the vascular smooth
muscle cells (VSMCs). Constriction of VSMCs results from
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increase in the Ca2+ sensitivity of the contractile apparatus
[1,2]. One key mechanism enhancing Ca2+ sensitivity and
thus vascular tone is Rho-kinase signalling, which results
in inhibition of myosin light chain phosphatase [2,3].
Rho-kinase activation has been shown to cause vasos-
pasm of coronary, cerebral and spiral modiolar arteries [4-
9].
One of the strongest Rho-kinase activators described so far
is the vasoconstrictor endothelin-1 (ET-1). The synthesis
of ET-1 by endothelial cells is activated by physiological
stimuli such as shear stress, insulin, thrombin and other
vascular factors [10]. ET-1 and ETA receptors play a funda-
mental role in the maintenance of basal vasomotor tone
in resistance arteries [11]. The synthesis of ET-1 can be
increased by hypoxia and elevated oxidized low-density
lipoproteins [12,13] and has been implicated in the
pathogenesis of a number of cerebrovascular disorders,
including stroke, ischemia, and, in particular, cerebral
vasospasm [14,15]. Thus, ET-1 possesses pathological
potential in addition to its physiological functions. ET-1 is
present in the SMA and induces strong, long-lasting con-
striction via ETA-receptor-mediated Rho-kinase activation
[9,16,17]. Taken together ET-1 is likely an endogenous
regulator of inner ear microvascular tone.
We have previously shown that CGRP is able to reverse
ET-1-induced constrictions in the SMA via an increase in
vascular smooth muscle cAMP [18]. CGRP is present in
perivascular nerves of the SMA and therefore is a potential
endogenous vasodilator of the SMA. We propose, there-
fore, that reversal of ET-1-induced constriction is not nec-
essarily limited to inhibition of ET-1-related mechanisms
(e.g., Rho-kinase signalling).
These findings provide a clinical perspective for a new
treatment of SSHL, because both Rho-kinase signalling
and cAMP can be targeted via pharmacological agents.
Therefore, we assessed the potency of clinically relevant
Rho-kinase inhibitors and a cell-permeable analogue
cAMP (dbcAMP) in terms of reversing ET-1-induced con-
striction and Ca2+-sensitization in the SMA.
Methods
Drugs and solutions
The physiologic salt solution (PSS) contained (in mmol/
L) 150 NaCl, 3.6 KC1, 1.0 MgCl2, 1.0 CaCl2, 5.0 HEPES,
and 5.0 glucose, pH 7.4. Extracellular Ca2+ concentration
([Ca2+]ex) was raised to 3 and 10 mmol/L by addition of
CaCl2. A maximal vasodilation was induced by the
removal of extracellular Ca2+. The nominally Ca2+-free
solution contained (in mmol/L) 150 NaCl, 3.6 KC1, 1.0
MgCl2, 1.0 EGTA, 5.0 HEPES, and 5.0 glucose, pH = 7.4.
Fluo-4-AM (Molecular Probes) was dissolved in anhy-
drous DMSO and stored in 1 mmol/L aliquots. Y-27632
was kindly provided by Welfide. Fasudil was obtained
from Calbiochem. Fasudil (obtained from Tocris Cook-
son) was modified to hydroxyfasudil by Dr. Duy Hua,
Dept of Chemistry, Kansas State University. All other
chemicals were obtained from Sigma.
Preparation of the spiral modiolar artery (SMA)
Experiments were conducted on tissues isolated from ger-
bils under a protocol that was approved by the Institu-
tional Animal Care and Use Committee at Kansas State
University. Gerbils were anesthetized with sodium pento-
barbital (100 mg/kg i.p.) and decapitated. Temporal
bones were removed, opened and placed into a micro-dis-
section chamber containing PSS at 4°C. The SMA was iso-
lated from the cochlea by micro-dissection as described
previously [19]. Briefly, the cochlea was opened. The bone
surrounding the modiolus was carefully removed and the
SMA, which is only loosely attached to the eighth cranial
nerve, was isolated. Care was taken to not stretch the
artery.
Simultaneous measurement of vascular diameter and 
[Ca2+]i
The simultaneous measurement of vascular diameter and
[Ca2+]i has been described previously [17]. Briefly, the
smooth muscle cells of vessel segments were loaded with
the Ca2+ indicator dye fluo-4 by incubation in PSS con-
taining 5 µmol/L fluo-4-AM for 35 min at 37°C. After
loading, vessel segments were washed with PSS and main-
tained at 4°C for 20 minutes prior to experimentation at
37°C. Vessel segments were transferred into a bath cham-
ber mounted on the stage of an inverted microscope
(Nikon). Fluorescence emitted by fluo-4 (518–542 nm)
in response to excitation at 488 nm (Photon Technology
International) was detected by a photon counter (Photon
Technology International). For measurements of the vas-
cular diameter, the vessel was illuminated at 605–615 nm
and the transmission image was recorded with a chilled
CCD camera (Hamamatsu). The outer vascular diameter
was measured by two video edge detectors (Crescent). Flu-
orescence and calibrated diameter signals were digitized
and recorded simultaneously (Photon Technology Inter-
national).
Experimental protocols
Experiments were started 20 min after loading with fluo-
4. Vessel segments were superfused at a rate of 9 ml/min
with PSS. This flow rate corresponds to an exchange rate
of 2 bath chambers volumes/sec, given the bath chamber
volume of 75 µl. Upon start of the superfusion, the
unpressurized artery develops a spontaneous vascular
tone that is sensitive to removal of extracellular Ca2+ and
inhibition of L-type Ca2+ channels with nanomolar con-
centrations of nifedipine [19]. The viability of each vesselPage 2 of 7
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Rho-kinase inhibitors reverse ET-1-induced constrictionFigure 1
Rho-kinase inhibitors reverse ET-1-induced constriction. A) Effect of 10 nmol/L endothelin-1 (ET-1) on the cytosolic 
Ca2+ concentration ([Ca2+]i) and the vascular diameter of the spiral modiolar artery. Note that ET-1 caused a transient 
increase in [Ca2+]i and a sustained vasoconstriction and increase in vasomotion. This constriction outlasted the stimulation with 
ET-1. Increasing extracellular Ca2+ concentration ([Ca2+]ex) to 10 mmol/L ("Ca") induced an increase in [Ca2+]i with parallel 
vasoconstriction. This increase of the [Ca2+]ex from 1 to 10 mmol/L ("Ca") served as a control experiment. Measurements of 
[Ca2+]i were normalized to the value obtained prior to the admission of ET-1 (value at time 'x' was set to 1). B) In the presence 
of 10 nmol/L ET-1, increasing concentrations of fasudil (1–100 µmol/L) induce dose-dependent relaxation. [Ca2+]i values were 
normalized, with the baseline value prior to application of ET-1 designated as 1.0 (denoted as "x"). C) Dose-response curves 
for Y-27632-, fasudil- and hydroxy-fasudil-induced reversal of ET-1 (10 nmol/L) -mediated vasoconstriction. C) ET-1 stimulated 
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[Ca2+]ex. The [Ca2+]i was monitored as fluorescence inten-
sity and was normalized to the basal fluorescent emission
prior to the beginning of each experiment. The fluores-
cence and diameter values taken for statistical analysis
represent averages of the [Ca2+]i-fluorescence and the vas-
cular diameter over 30 sec beginning 30 sec after the onset
of stimulation. We carefully validated the [Ca2+]i -meas-
urements with the non-ratiometric Ca2+-dye fluo-4 by (i)
excluding artefacts due to vessel diameter changes (evalu-
ated by [Ca2+]ex-versus ET-1 dose-response curves), (ii)
excluding significant differences in the magnitude of
[Ca2+]i -changes between preparations, and (iii) assessing
the same optimal dye-loading conditions in each experi-
ment [9,17].
Affinity constants (KDB) and concentrations that cause a
half-maximal inhibition (IC50) were determined in cumu-
lative experiments and averaged after logarithmic trans-
formation (pKDB and pIC50) as previously described [17].
The Ca2+ sensitivity of the contractile apparatus was deter-
mined by a correlation of [Ca2+]i and the vascular diame-
ter as described previously [9]. Changes in [Ca2+]i were
induced by changes in [Ca2+]ex. Stepwise increases in
[Ca2+]ex from 0 to 1, 3 and 10 mmol/L caused increases in
[Ca2+]i and decreases in the vascular diameter. Correla-
tions were found to be linear (r > 0.95) within the meas-
ured range (the relation between calcium concentration
and tension gets sigmoidal if the [Ca2+]ex and thus the
[Ca2+]i is further increased [9]). Slopes were quantified in
the arbitrary unit µm/Ca2+, where µm represent the
change in the vascular diameter and Ca2+ represents the
normalized change in the cytosolic Ca2+ concentration.
Linear slopes were obtained to compare the Ca2+ sensitiv-
ity within paired experiments. In each vessel segment, the
Ca2+ sensitivity was assessed under control and under
experimental conditions.
Experiments of dbcAMP induced dilations were bracketed
by Ca2+ free manoeuvres that were performed to induce a
maximal vasodilation and reduce the [Ca2+]i to a minimal
level. Vascular diameter or fluorescence intensity in the
absence of Ca2+ was considered as baseline. The magni-
tude of the vascular tone or fluorescence intensity was
determined as the difference between the recorded value
and the baseline value. Measurements were averaged over
a period of 1 min to average vasomotion. DbcAMP-
induced effects were normalized to the magnitude of the
vascular tone or fluorescence intensity during 1 min
immediately prior to the application of dbcAMP.
Statistical analysis
All results are expressed as average ± SEM of n experiments
with n representing the number of vessel segments. The
significance of changes in the vascular diameter and of
changes in the Ca2+ sensitivity were determined using Stu-
dent's paired t-test. Differences were considered to be sig-
nificant at error probabilities less than 0.05 (P < 0.05).
Results
This report is based on recordings of 50 vessels from 34
animals. The average vascular diameter was 65 ± 1 µm.
ET-1-induced constriction is reversed via Rho-kinase 
inhibitors
ET-1 (10 nmol/L) induced a transient increase in [Ca2+]i,
a strong and long-lasting vasoconstriction and a robust
increase in the vasomotion of the gerbil spiral modiolar
artery (Fig. 1A). The [Ca2+]i returned to almost resting lev-
els after the transient increase, while the constriction was
maintained. The ET-1-induced vasoconstriction was not
readily reversible upon removal of ET-1 from the per-
fusate. The constriction and the increased vasomotion
were observed without a significant change for at least 20
minutes after removal of ET-1 from the superfusate (data
not shown). Note that ET-1-induced a transient [Ca2+]i
increase and a sustained vasoconstriction while exposure
to 10 mmol/l Ca2+ induced an increase in [Ca2+]i and a
parallel vasoconstriction.
We tested the potency of different Rho-kinase inhibitors
reversing ET-1-induced constriction. Figure 1B shows an
original recording of an ET-1-induced constriction which
is antagonized by increasing concentrations of fasudil.
Fasudil mediated vasodilation were induced without sig-
nificantly altering [Ca2+]i-levels. The Rho-kinase inhibi-
tors Y-27632, fasudil and hydroxy-fasudil reversed ET-1-
induced constriction (10 nmol/L) in a dose-dependent
manner (Figure 1C). The 1C50 for Y-27632-, fasudil- and
hydroxy-fasudil- mediated reversion of constriction was 3
µmol/L (pIC50 = 5.50 ± 0.31; n = 6), 15 µmol/L (pIC50 =
4.71 ± 0.13; n = 7) and 111 µmol/L (pIC50 = 3.95 ± 0.24;
n = 6), respectively. The Ca2+ sensitivity of the contractile
apparatus was assessed as linear slopes obtained from cor-
relations of [Ca2+]i and vascular diameter. ET-1 (100
pmol/L) increased the Ca2+ sensitivity (-36 ± 9 versus -62
± 13 µm/Ca2+, n = 8; Figure 1D), fasudil (3 µmol/L) pre-
vented the ET-1-induced increase in the Ca2+ sensitivity (-
17 ± 3 versus -16 ± 2 µm/Ca2+, n = 8, Figure 1E). Taken
together, these observations demonstrate that ET-1-
induced constriction in the SMA is maintained by a Rho-
kinase-mediated increase of the Ca2+ sensitivity of the
contractile apparatus, which can be effectively reversed by
Rho-kinase inhibition.
Exogenous, cell-permeable cAMP (dbcAMP) reverses ET-
1-induced constriction and Ca2+sensitization
DbcAMP induced dose-dependant decreases in [Ca2+]i
and reversal of constriction induced by 1 nmol/L ET-1Page 4 of 7
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± 0.09 and 6.49 ± 0.07, n = 8, Fig. 2A and 2B), respectively.
Note that dbcAMP-induced decreases in [Ca2+]i were less
pronounced than those induced by removal of Ca2+ from
the extracellular solution although dilations were compa-
rable (Fig. 2A). This observation suggests that the dilatory
effect of cAMP is at least in part due to a decrease of the
Ca2+ sensitivity of the contractile apparatus. Consistent
with this interpretation is the apparent rightward shift of
the dose-response curve of dbcAMP for change in [Ca2+]i
(Fig. 2B). If cAMP and ET-1 have opposing effects on the
Ca2+ sensitivity, it should be possible to prevent the ET-1-
induced increase in the Ca2+ sensitivity with dbcAMP.
Indeed, 10 µmol/L dbcAMP prevented the increase in the
Ca2+ sensitivity induced by 100 pmol/L ET-1 (-29 ± 4 ver-
sus -27 ± 3 µm/Ca2+, n = 7; Figure 2C). These observations
support the hypothesis that cAMP and Rho-kinase can
interact as functional antagonists at the level of the Ca2+
sensitivity of the contractile apparatus.
Discussion
The primary observation of the present study is that the
ET-1-induced SMA vasoconstriction is reversed by the
Rho-kinase inhibitors Y-27632, fasudil and hydroxy-fas-
udil and by the cAMP analogue dbcAMP. All four agents
decreased VSMC contractile apparatus Ca2+ sensitivity.
In general, ET-1-induced constriction has been found to
be elicited by different Ca2+ mobilizing mechanisms,
including Ca2+ release from intracellular Ca2+ stores via a
phospholipase C mediated activation of IP3-receptors and
activation of L-type and non-selective Ca2+ channels [20-
22]. Ca2+ mobilization has been considered to be the
main mechanism of ET-1-induced constriction. In con-
trast, according to our previous results, ET-1-induced Ca2+
mobilization in the SMA appears to play a minor role
[17]. The major mechanism of ET-1-induced constriction
is an increase in the Ca2+ sensitivity of the contractile
apparatus [9].
The increase in the Ca2+ sensitivity appears to be mediated
by a Rho-kinase dependent inactivation of MLCP. This
hypothesis is supported by two observations. First, inhibi-
tion of Rho-kinase with the selective Rho-kinase inhibitor
Y-27632 abolished the ET-1-induced increase in the Ca2+
sensitivity. Y-27632 at concentrations of up to 10 µmol/L
has been shown to be a selective Rho-kinase inhibitor [23-
25]. Second, inhibition of Rho-kinase with the selective
Rho-kinase inhibitors fasudil and its functional metabo-
lite hydroxy-fasudil also reversed ET-1-induced constric-
tion and Ca2+ sensitization of the contractile apparatus.
These inhibitors have also been shown to be selective
Rho-kinase inhibitors up to 20 µmol/L [24,26,27]. Since
dbcAMP reverses ET-1 (1 nmol/L) -induced vasoconstriction in a dose-dependent mannerFigure 2
dbcAMP reverses ET-1 (1 nmol/L) -induced vasoconstriction in a dose-dependent manner. A) A representative 
recording of [Ca2+]i-diameter measurements. The [Ca2+]i was normalized to the value prior to application of ET-1 (value at 
timepoint "x" was set to 1.0). Maximal vasodilation was determined by exposure of the SMA to Ca-free conditions ("0Ca"). An 
increase of extracellular Ca2+ to 10 mmol/L ("Ca") induced a [Ca2+]i increase and parallel vasoconstriction. B) Dose-response 
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unique, but were observed to have similar functional
effects, the concern of non-specific effects of the inhibitors
can be minimized.
It has been shown that the Rho-kinase-dependent inhibi-
tion of the MLCP results from phosphorylation of the
myosin-binding subunit (MBS) of the enzyme [28]. All
Rho-kinase inhibitors employed in the present study
reversed ET-1-induced constriction, with a clinically rele-
vant EC50 range below the level reported to cause systemic
side effects (especially hypotension). This possibly indi-
cates that basal Rho-kinase activity is rather low under
normal conditions [23,29]. Thus, an up-regulation of
Rho-kinase expression/activity under pathophysiological
conditions (hypertension, cerebral and coronary vasos-
pasm) would impart Rho-kinase inhibitors with pharma-
cological relevance [29].
We show that cAMP is a potent vasodilating second mes-
senger in the SMA, acting by mechanisms which decrease
[Ca2+]i and Ca2+ sensitivity. Although cAMP reduces intra-
cellular Ca2+ levels, the present data demonstrate that the
main pathway targets the Ca2+ sensitivity of the contractile
apparatus. This interpretation is consistent with findings
obtained in other preparations such as permeabilized
intestinal and bronchial smooth muscle. In these studies
the authors also could show that cAMP mediates a Ca2+
desensitization of the contractile apparatus [30,31]. cAMP
seems to be the main second messenger of CGRP-induced
Ca2+ desensitization and vasodilation in the SMA [18].
The data supports our hypothesis that the reversal of ET-
1-induced constriction is not limited to inhibition of ET-
1-related mechanisms (e.g., Rho-kinase signalling) and
that ET-1-independent mechanisms can be targeted phar-
macologically to reverse ET-1-mediated constriction. Clin-
ical relevance arises from the possibility of modulating
pharmacologically VSMC cAMP concentrations.
Conclusion
Although the sudden loss of hearing causes substantial
distress and pronounced long-term effects in affected
individuals, adequate strategies to clinically treat the dis-
order are lacking. One subgroup of SSHL is believed to
arise from SMA vasospasm(s) which ultimately lead to
ischemic stroke of the inner ear [32]. The targeting of two
distinct signalling mechanisms, Rho-kinase and cAMP,
were both effective in reversing SMA constriction. Of note,
two of the agents employed in the present study (fasudil
and hydroxy-fasudil) are currently used in the clinical set-
ting and were found to be effective at concentrations
below the threshold of systemic side effects [8,33]. Thus,
this study presents two novel, clinically relevant
approaches for the treatment of SSHL. We therefore pro-
pose that clinical investigation into the use of these agents
for SSHL treatment is warranted.
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